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Abstract
Background: Joint arthroplasty patients have a high prevalence of co-morbidities and this impacts their surgical
outcomes. There are different ways to ascertain co-morbidities and appropriate measurement is necessary. The
purpose of this study was to: (1) describe the prevalence of co-morbidities in a cohort of total hip arthroplasty
(THA) and knee arthroplasty (TKA) patients using two diagnoses-based measures (Charlson and Elixhauser) and one
prescription-based measure (RxRisk-V); (2) compare the agreement of co-morbidities amongst the measures.
Methods: A cross-sectional study of Australian veterans undergoing THAs (n = 11,848) and TKAs (n = 18,972) between
2001 and 2012 was conducted. Seventeen co-morbidities were identified using the Charlson, 30 using the Elixhauser,
and 42 using the RxRisk-V measure. Agreement between co-morbidities was calculated using Kappa (κ) statistics.
Results: Combining measures, 64 conditions were identified, of these 28 were only identified using the RxRisk-V,
11 using the Elixhauser, and 2 using the Charlson. The most prevalent conditions was pain treated with anti-
inflammatories (58.7 % THAs, 55.9 % TKAs), pain treated with narcotics (55.0 % THAs, 50.9 % TKAs), hypertension
(56.0 % THAs and TKAs), and anticoagulation disorders (53.0 % THAs, 48.6 % TKAs). Diabetes was the only condition
with substantial agreement (all κ > 0.6) amongst all measures. When comparing the diagnoses based algorithms,
agreement was high for overlapping conditions (all κ > 0.71).
Conclusions: Different measures identified different co-morbidities, provided different estimates for the same
co-morbidity, and had different levels of agreement for common co-morbidities. This highlights the importance of
understanding co-morbidity measures and using them appropriately in studies and case-mix adjustments analyses.
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Background
The prevalence of multi-morbidity is increasing [1, 2],
thus the number of patients with multiple co-morbidities
undergoing total joint arthroplasty has also increased in
the last two decades [3, 4]. Studies in the United States
(US) report multiple co-morbidities in 62 % of patients
over 65 years old and this was associated with higher
healthcare utilisation, cost, and overall impairment of
patients [2]. In the US in the mid-2000s, patients older
than 65 years undergoing total joint arthroplasty had an
average of two co-morbidities when measured by the
diagnosis based Elixhauser co-morbidity measure [3, 4].
The number of co-morbidities as well as specific condi-
tions are related to patients’ surgical outcome during total
joint arthroplasty [5–12].
Appropriate measurement of patient co-morbidities in
those undergoing joint arthroplasty is critical because of
the high prevalence of co-morbidities, the higher service
utilisation, and the poorer surgical outcomes in those
patients. Several co-morbidity measures exist [13–15].
The validated and most frequently used diagnostic based
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coding measure have been shown to be predictive of sev-
eral healthcare outcomes in different study populations
(including orthopaedics and other disciplines) and are
used in case mix adjustment [15, 16]. Two of the most
commonly used co-morbidity measures in health services
and orthopaedics research are the Charlson [17] and
Elixhauser [18] measures. Both measures have been used
in studies evaluating total joint arthroplasty patients.
Prescription medication based co-morbidity measures,
such as the RxRisk-V [19] and Medication Based Disease
Burden Index [20], were also developed to estimate the
prevalence of co-morbidities in different populations and
have been used in case mix adjustment and outcome
prediction. However, to our knowledge, no previous study
has evaluated the prevalence of co-morbidities in a total
joint arthroplasty sample using a validated prescription-
based coding measure.
Each method to ascertain co-morbidities has different
strengths and limitations. For example, pharmacy based
measures may provide more detailed information on
active chronic conditions for which patients are actually
receiving care and not only serious conditions that
diagnostic based measures may identify. Further, dif-
ference in coding practices between countries may
make one measure more relevant in a certain country.
In Australia, for example, the use of the diagnoses
based measures is limited to inpatient encounters as
outpatient encounters are not recorded using the
same coding system necessary for identification of the
conditions. Additionally, in Australia and the US,
hospital coding does not have an official mechanism to
include diagnoses other than those relevant to the hospital
stay [21]. This is probably avoided by countries such as
the United Kingdom, which implemented in 2010 a list of
required comorbidities that must be reported at the time
of hospitalisation [15].
It is clinically and scientifically important to have an
accurate, comprehensive, and standardized method to
identify the presence of co-morbidities at the time of
surgery for several reasons. One reason is to inform
surgeons, healthcare workers, and patients on the proper
course of treatment and risk of procedure, especially
when multiple co-morbidities are present. Another is for
standardizing research, specifically when evaluating
outcomes in different cohorts of patients where proper
case mix adjustment must be conducted to assure cohorts
can be properly compared. Our study sought to (1) deter-
mine the prevalence of co-morbidities in an Australian co-
hort of total hip arthroplasty (THA) and total knee
arthroplasty (TKA) patients using two diagnoses based co-
morbidity measures (Charlson [17] and Elixhauser [18])
and one prescription based measure (RxRisk-V [19, 22])
and (2) compare the agreement of individual co-
morbidities amongst the measures.
Methods
Study design, setting, and sample
A cross-sectional study was conducted on a cohort of
THA and TKA patients, who had their procedures
between 2001 and 2012. Patients receiving care subsi-
dised by the Australian Government Department of
Veterans’ Affairs (DVA) were included in the study. De-
identified administrative inpatient encounter information
and prescription medicine (inpatient and outpatient)
data for this captured population was used.
The study sample included patients aged ≥18 years
old, who had all health services subsidised by DVA, and
underwent elective primary unilateral THA procedures
identified using International Classification of Disease,
10th Revision, Australian Modification (ICD-10-AM)
code 4931800 and elective primary unilateral TKA
procedures identified using ICD-10-AM codes 4951800,
4952100, 4952102, 4952400.
Co-morbidity measures and data sources
The RxRisk-V [19] is a co-morbidity prescription based
measure that uses patients’ medication histories to
determine the presence of 45 conditions [22]. This
measure has been shown to be predictive of cost of care
[19, 22] and mortality [23–25] in different patient sam-
ples using both inpatient and outpatient pharmacy data
[23, 25]. In this study a modified RxRisk-V was used
with 42 conditions; the conditions ostomy, neurogenic
bladder, and urinary incontinence were excluded.
The Charlson co-morbidity measure typically uses
inpatient hospitalisations over a specified time period to
identify the presence of 17 conditions and calculate an
overall comorbidity score [21, 26]. The Charlson score
was originally developed to predict mortality and assist
with case mix adjustment in regards to this outcome,
but has been applied to several other outcomes now,
including some surgical outcomes [16, 27].
The Elixhauser co-morbidity measure also typically
uses inpatient hospitalisations during a specific period to
calculate co-morbidities. The most common form of this
measure identifies the presence of 30 conditions and has
been evaluated as a predictor of blood transfusions,
length of stay, and mortality [26, 28]. This measure was
developed by the Agency for Healthcare Research and
Quality (AHRQ) Healthcare Cost and Utilisation Project
and is widely used in health services research [18, 29].
The RxRisk-V and Charlson have 6 common conditions,
the Elixhauser and RxRisk-V have 10 common conditions,
and the Charlson and Elixhauser have 12.
Using the DVA administrative database all inpatient
hospitalisations and prescription medicine history were
identified for the study sample. The database contains
details of all prescription medications, medical, allied
health services and hospitalisations provided to veterans
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for which DVA pays a subsidy. In the dataset, medications
are coded according to the World Health Organization
Anatomic, Therapeutic and Chemical Classification,
and the Pharmaceutical Benefits Schedule item codes.
Hospitalisations are coded according to the ICD-10-AM.
DVA also maintains a client file, which contains informa-
tion on gender, date of birth, date of death, and family
status for a treatment population that in September 2011
was 242,000 people.
In this study, the 12 month period preceding the
discharge date of the arthroplasty procedure was used to
ascertain the co-morbidities according to the two
diagnoses based co-morbidity measures (Charlson and
Elixhauser) using DVA hospital records. The arthro-
plasty procedure hospitalisation was included in the
calculation of the diagnostic co-morbidity measures. The
12 month prescription dispensing history preceding the
admission date for the arthroplasty procedure was uti-
lised to measure RxRisk-V.
Statistical analysis
Frequencies, proportions, means, standard deviations
(SD), medians and interquartile ranges (IRQs) were used
to describe the sample. Prevalence of co-morbidities by
each measure was calculated. Agreement between spe-
cific co-morbidity indicators between measures (where
conditions were common) was calculated using Kappa (κ)
statistics and 95 % confidence intervals (CI). κ agreement
thresholds used were: slight: 0.01 ≤ κ ≤ 0.20, fair: 0.21 ≤ κ ≤
0.40, moderate:0.41 ≤ κ ≤0.60, substantial: 0.61 ≤ κ ≤ 0.80,
almost perfect: 0.80 ≤ κ ≤ 0.99, perfect: κ =1.0 [30]. SAS 9.4
(SAS Institute, Cary, NC, USA) was used for all analyses.
This study has ethics approval from the Australian DVA
and University of South Australia human research ethics
committees. The ethics committees also waived the re-
quirement for informed consent.
Results
During the study period 11,848 patients underwent THA
and 18,972 TKAs. Both cohorts had a slightly higher
proportion of males (50.2 % THA and 52.3 % TKA) than
females and procedures were mostly performed in private
hospitals (95.6 % THA and 96.6 % TKA). The median age
was 80.9 (IQR 76.4-84.4) years old for patients with THAs
and 79.8 (IQR = 74.7-83.5) years old for patients with
TKAs. See Table 1 for sample details.
The mean number of RxRisk-V, Elixhauser, and
Charlson co-morbidities in the THA (5.5 (SD = 3.3), 0.9
(SD = 1.3), 0.4 (SD = 0.8), respectively) and TKA (5.4
(SD = 3.5), 0.9 (SD = 1.2), 0.4 (SD = 0.7), respectively) co-
horts was similar. The three most common co-morbidities
identified by the RxRisk-V were also similar between the
THA and TKA cohort, and included: the musculoskeletal
conditions of pain treated with anti-inflammatories
(58.7 % THA, 55.9 % TKA) and pain treated with
narcotics (55.0 % THA, 50.9 % TKA), and cardiovascular
diseases that involved treatment with anticoagulation
agents (52.6 % THA, 48.4 % TKA). Using the Elixhauser
measure, the three most prevalent co-morbidities in
patients having a THA were: hypertension (22.0 %),
arrhythmias (14.7 %), and fluid and electrolyte disorders
(7.5 %); in patients with TKAs the conditions were: hyper-
tension (23.4 %), arrhythmias (13.5 %), and diabetes with
chronic complications (7.7 %). Using the Charlson meas-
ure the three more prevalent co-morbidities of THA and
TKA patients were: uncomplicated diabetes (7.1 % THA,
8.1 % TKA), diabetes with chronic complications (6.3 %
THA, 7.3 % TKA), and chronic pulmonary disease (5.5 %
THA, 4.5 % TKA). See Table 2 for co-morbidities by the
three measures and overall prevalence of conditions.
Combining all measures, 64 unique co-morbidities were
identified, of these 28 were only identified using the RxRisk-
V, 11 using the Elixhauser, and 2 using the Charlson. The
most prevalent co-morbidities only identified by the
RxRisk-V included: pain treated with anti-inflammatories,
pain treated with narcotics, gastric acid disorder, hyperlipid-
aemia, ischemic heart disease (both in combination with an-
gina and hypertension), diseases treated with antiplatelets
agents, and reactive airway disease. The most prevalent
co-morbidities only identified by the Elixhauser included
fluid and electrolyte disorders, obesity, valvular disease,
history of solid tumour, deficiency anaemia, and obesity.
The co-morbidities only identified by Charlson were
cerebrovascular disease and myocardial infarction. See
Table 2 other co-morbidities specific to each measure.
There was a relationship between co-morbidity measures
for common indicators (Table 3). RxRisk-V and the Elix-
hauser, diabetes was the only co-morbidity with substantial
agreement between the two measures (κ = 0.63, 95 % CI
0.60-0.65 for THA, κ = 0.61, 95 % CI 0.59-0.63 for TKA).
Similarly, when comparing the RxRisk-V and Charlson
measures, diabetes was also the only co-morbidity with
substantial agreement ((κ = 0.63, 95 % CI 0.60-0.65 for
THAs, κ = 0.61, 95 % CI 0.59-0.63 for TKAs). When com-
paring the two diagnostic based measures, the Charlson
and Elixhauser, for conditions that did not have identical
coding, the agreement was almost perfect for uncompli-
cated diabetes, diabetes with chronic complications, peptic
ulcer disease, rheumatoid arthritis, and renal failure. Mild
liver disease had substantial agreement between the Charl-
son and Elixhauser (κ = 0.71, 95 % CI 0.56-0.85 for THA
and κ = 0.76, 95 % CI 0.67-0.86 for TKA).
Discussion
The co-morbidity measures evaluated in this study yielded
a different prevalence of co-morbidities and a wider
variation of agreement between common conditions. In
our sample of joint arthroplasty patients, the most
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common non-musculoskeletal related co-morbidities were
hypertension, disorders that required anticoagulation
agents, and gastric acid disorders. We also found that
except for diabetes, which had good agreement between
all three co-morbidity measures, there was low agreement
between the prescription based RxRisk-V and the diagno-
ses based Elixhauser and Charlson co-morbidity measures
for common conditions. As expected, between the diagno-
ses based measures there was substantial agreement be-
tween common co-morbidities.
The prevalence of co-morbidities identified using all
three measurements had some commonalties and differ-
ences with previous estimates in large cohorts of joint
arthroplasty patients. Some of the differences are attrib-
uted to the method of co-morbidity ascertainment in
different studies. The Elixhauser was the more commonly
used measure in the published literature, such as Cram et
al.’s US Medicare studies [3, 4], Kapoor et al.’s US DVA
study [31], the Kaiser Permanente Total Joint Replace-
ment registry studies [32, 33], and the US California and
New York states cohort studies by Dy et al. [34, 35]. But
other studies have used different measures, such as an US
Medicare TKA study that used a combination of the
Charlson and Elixhauser [5], and a Finish arthroplasty
registry study that used a non validated measure inclusive
of diagnostic codes, medication prescriptions, and drug
reimbursement for certain conditions [36]. Most studies
reported similar high prevalence of hypertension (range
43–70 %) [5, 31–35], but the Finish study reported a lower
prevalence (17.7 % in THA and 20.8 % in TKA) than these
cohorts and ours [36]. The prevalence of diabetes was also
similar between our cohort (approximately 10–13 %) and
those of the US California and New York states studies
(9 % in the THAs and 14 % in TKAs), US Medicare THA
cohort (10-15 % recent estimates) and the Finish arthro-
plasty registry cohort (5.5–7.5 %) [3, 35, 36]. This
prevalence was lower, however, than those reported by
other US cohorts (Kaiser Permanente registry 18–26 %,
Medicare TKA patients 22 %, and DVA patients 26.5 %)
[4, 5, 31–33]. The Kaiser Permanente registry ascertained
diabetes using the institution’s diabetes registry, instead of
the Elixhauser, which could contribute to the higher
prevalence reported [37]. The prevalence of congestive
heart failure (approximately 13 %) was also similar to that
Table 1 Total hip and knee arthroplasty patients characteristics, 2001–2012
Total hip arthroplasty Total knee arthroplasty
N (%) N (%)
Total 11,848 100.0 18,972 100.0
Gender Females 5,898 49.8 9,047 47.7
Males 5,950 50.2 9,925 52.3
Age, years (median, IQR) 80.9 76.4–84.4 79.8 74.7–83.5
THA diagnoses (ICD-10-AM code) Other primary coxarthrosis (M161) 9,648 81.4 - -
Coxarthrosis unspecified (M169) 1,109 9.4 - -
Unspecified osteonecrosis pelvis thigh (M8795) 343 2.9 - -
Other 748 6.3
TKA Diagnosis (ICD-10-AM Code) Other primary gonarthrosis (M171) - - 16,329 86.1
Gonarthrosis unspecified (M179) - - 1,437 7.6
Primary gonarthrosis bilateral (M170) - - 489 2.6
Other - - 717 3.8
Number of RxRisk-V co-morbidities 0 1,466 12.4 3,290 17.3
1–2 747 6.3 938 4.9
3–4 2,041 17.2 2,785 14.7
5–6 2,888 24.4 4,398 23.2
≥7 4,706 39.7 7,561 39.9
Number of Elixhauser co-morbidities 0 6,087 51.4 9,910 52.2
1–2 4,333 12.1 7,034 37.1
≥3 1,428 12.1 2,028 10.7
Number of Charlson co-morbidities 0 8,529 72.0 13,917 73.4
1–2 2,946 24.9 4,628 24.4
≥3 373 3.1 427 2.3
IQR interquartile range, THA total hip arthroplasty, TKA total knee arthroplasty, ICD-10-AM International Classifications of Disease, 10th Revision, Australian Modification
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Table 2 Mean total scores and prevalence of individual conditions by each co-morbidity measure and total computation
Total hip arthroplasty (N = 11,848) Total knee arthroplasty (N = 18,972)
RxRisk-V Elixhauser Charlson Total RxRisk-V Elixhauser Charlson Total
Mean score (SD) 5.5 (3.3) 0.9 (1.3) 0.4 (0.8) 6.2 (3.6) 5.4 (3.5) 0.9 (1.2) 0.4 (0.7) 6.1 (3.7)
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Cancer
Lymphoma - 42 (0.4) - 42 (0.4) - 33 (0.2) - 33 (0.2)
Malignancies 423 (3.6) 257 (2.2) 648 (5.5) 757 (4.0) 285 (1.5) 1,004 (5.3)
Metastatic cancer - 60 (0.5) 60 (0.5) 60 (0.5) - 43 (0.2) 43 (0.2) 43 (0.2)
Solid tumor without metastatis - 303 (2.6) - 306 (2.6) - 398 (2.1) - 398 (2.1)
Cardiovascular/blood
Anticoagulation agents/coagulopathy 6,230 (52.6) 130 (1.1) - 6,274 (53.0) 9,177 (48.4) 168 (0.9) - 9,227 (48.6)
Antiplatelets agents 3,975 (33.5) - - 3,975 (33.5) 6,055 (31.9) - - 6,055 (31.9)
Arrhythmias 1,206 (10.2) 1,744 (14.7) - 2,313 (19.5) 1,766 (9.3) 2,561 (13.5) - 3,427 (18.1)
Cerebrovascular disease - - 273 (2.3) 273 (0.3) - - 353 (1.9) 353 (1.8)
Congestive heart failure 1,454 (12.3) 471 (4.0) 471 (4.0) 1,636 (13.8) 2,142 (11.3) 608 (3.2) 608 (3.2) 2,452 (12.9)
Hyperlipidaemia 4,377 (36.9) - - 4,377 (36.9) 7,115 (37.5) - - 7,115 (37.5)
Hypertensiona 5,644 (47.6) 2,612 (22.0) - 6,638 (56.0) 8,866 (46.7) 4,433 (23.4) - 10,629 (56.0)
Ischemic heart disease/angina 1,375 (11.6) - - 1,375 (11.6) 2,054 (10.8) - - 2,054 (10.8)
Ischemic heart disease/hypertension 4,054 (34.2) - - 4,054 (34.2) 6,329 (33.4) - - 6,329 (33.4)
Myocardial infarction - - 333 (2.8) 333 (2.8) - - 410 (2.2) 410 (2.2)
Peripheral vascular disease - 299 (2.5) 299 (2.5) 299 (2.5) - 346 (1.8) 346 (1.8) 346 (1.8)
Pulmonary circulation disorders - 136 (1.1) - 136 (1.2) - 288 (1.5) - 288 (1.5)
Valvular disease - 308 (2.6) - 308 (2.6) - 414 (2.2) - 414 (2.2)
Endocrine
Diabetes (uncomplicated) 905 (7.6) 755 (6.4) 838 (7.1) 1,271 (10.7) 1,782 (9.4) 1,405 (7.4) 1,530 (8.1) 2,423 (12.8)
Diabetes (complicated) - 794 (6.7) 747 (6.3) 794 (6.7) - 1,452 (7.7) 1387 (7.3) 1,452 (7.7)
Hypothyroidism 788 (6.7) 67 (0.6) - 801 (6.8) 1339 (7.1) 95 (0.5) - 1,369 (7.2)
Pancreatic insufficiency 20 (0.2) - - 20 (0.2) 31 (0.2) - - 31 (0.2)
Gastrointestinal
Gastric acid disorder 5,307 (44.8) - - 5,307 (44.8) 8,436 (44.5) - - 8,436 (44.5)
Inflammatory bowel syndrome 118 (1.0) - - 118 (1.0) 180 (1.0) - - 180 (1.0)
Hepatitis C 0 (0.0) - - 0 (0.0) 0 (0.0) - - 0 (0.0)
Liver disease (mild) - 25 (0.2) 26 (0.2) 33 (0.3) - 42 (0.2) 47 (0.2) 55 (0.3)
Liver disease (severe) or failure 479 (4.0) - 11 (0.1) 487 (4.1) 542 (2.9) - 9 (<0.01) 551 (2.9)
Peptic ulcer disease - 83 (0.7) 119 (1.0) 119 (1.0) - 102 (0.5) 155 (0.8) 155 (0.8)
Muscuoskeletal/pain related
Gout 1,187 (10.0) - - 1,187 (10.0) 2,210 (11.6) - - 2,210 (11.7)
Migraine 37 (0.3) - - 37 (0.3) 104 (0.5) - - 104 (0.6)
Osteoporosis/Pagets 1,463 (12.3) - - 1,463 (12.3) 2,017 (10.6) - - 2,017 (10.6)
Pain 6,512 (55.0) - - 6,512 (55.0) 9,663 (50.9) - - 9,663 (50.9)
Pain/Inflammation 6,958 (58.7) - - 6,958 (58.7) 10,611 (55.9) - - 10,611 (55.9)
RA/collage vascular disorders - 197 (1.7) 176 (1.5) 197 (1.7) - 348 (1.8) 320 (1.7) 349 (1.8)
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reported by one study reporting on the US TKA Medicare
cohort (10 %) [6], but higher than all other studies
reviewed (range 2.6–5.2 %) [3, 4, 31–36]. Conversely, the
prevalence of chronic obstructive pulmonary disease in
our sample (5–6 %) was lower than that reported by al-
most all cohorts (range 11–18 %) [6, 31, 34, 35] but the
Finish arthroplasty register cohort (6–8 %) [36]. While
there are obvious differences in the cohorts of patients in
these studies, disease prevalence differences are also due
to how they were identified- highlighting the need for
consideration in how co-morbidities are determined.
There was only a strong agreement between the co-
morbidities identified by the Risk-V and the Elixhauser
(10 common conditions) and Charlson (6 common
Table 2 Mean total scores and prevalence of individual conditions by each co-morbidity measure and total computation
(Continued)
Neurologic
Dementia 92 (0.8) - 209 (1.8) 249 (2.1) 94 (0.5) - 195 (1.0) 237 (1.3)
Epilepsy 535 (4.5) - - 535 (4.5) 838 (4.4) - - 838 (4.4)
Paralysis (or Paraplegia/Hemiplegia) - 86 (0.7) 86 (0.7) 86 (0.7) - 112 (0.6) 112 (0.6) 112 (0.6)
Parkinson’s disease 198 (1.7) - - 198 (1.7) 367 (1.9) - - 367 (1.9)
Other neurological disorders - 155 (1.3) - 155 (1.3) - 205 (1.1) - 205 (1.1)
Nutritional/obesity
Blood loss anaemia - 84 (0.7) - 84 (0.7) - 67 (0.4) - 67 (0.4)
Deficiency anaemia - 203 (1.7) - 203 (1.7) - 223 (1.2) - 223 (1.2)
Fluid and electrolyte disorders - 890 (7.5) - 890 (7.5) - 1,095 (5.8) - 1,095 (5.8)
Hyperkalaemia 8 (0.1) - - 8 (0.1) 18 (0.1) - - 18 (0.1)
Malnutrition 22 (0.2) - - 22 (0.2) 37 (0.2) - - 37 (0.2)
Obesity - 194 (1.6) - 194 (1.6) - 500 (2.6) - 500 (2.6)
Weight loss - 123 (1.0) - 123 (1.0) - 99 (0.5) - 99 (0.5)
Psychological/behavioural
Alcohol abuse/dependence 11 (0.1) 113 (1.0) - 120 (1.0) 27 (0.1) 177 (0.9) - 193 (1.0)
Anxiety and tension 1,459 (12.3) - - 1,459 (12.3) 2,344 (12.3) - - 2,340 (12.3)
Bipolar disorder 30 (0.3) - - 30 (0.3) 49 (0.3) - - 49 (0.3)
Depression 2,598 (21.9) 213 (1.8) - 2,667 (22.5) 4,484 (23.6) 293 (1.5) - 4,567 (24.1)
Drug abuse 14 (0.1) - 14 (0.1) 20 (0.1) - 20 (0.1)
Psychotic illness/psychoses 250 (2.1) 16 (0.1) - 259 (2.2) 391 (2.1) 22 (0.1) - 404 (2.1)
Smoking cessation 102 (0.9) - - 102 (0.9) 159 (0.8) - - 159 (0.8)
Renal/urologic
Benign prostatic hypertrophy 445 (3.8) - - 445 (3.8) 731 (3.9) - - 731 (3.9)
Renal disease/failure 162 (1.4) 436 (3.7) 388 (3.3) 560 (4.7) 290 (1.5) 575 (3.0) 524 (2.8) 826 (4.4)
Respiratory
Chronic pulmonary disease - 652 (5.5) 651 (5.5) 652 (5.5) - 858 (4.5) 856 (4.5) 858 (4.5)
Reactive airway disease 2,461 (20.8) - - 2,461 (20.8) 3,815 (20.1) - - 3,815 (20.1)
Tuberculosis 0 (0.0) - - 0 (0.0) 1 (<0.01) - - 1 (<0.01)
Miscellaneous
Allergies 1,660 (14.0) - - 1,660 (14.0) ,3046 (16.1) - - 3,046 (16.1)
Glaucoma 1,091 (9.2) - - 1,091 (9.2) 1,642 (8.7) - - 1,642 (8.7)
HIV/AIDS 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Psoriasis 63 (0.5) - - 63 (0.5) 103 (0.5) - - 103 (0.5)
Steroid-responsive conditions 1,889 (15.9) - - 1,889 (15.9) 3,345 (17.6) - - 3,345 (17.6)
Transplant 3 (<0.01) - - 3 (<0.01) 3 (<0.01) - - 3 (<0.01)
SD standard deviation, CI confidence interval, RA rheumatoid arthritis, HIV/AIDS human immunodeficiency virus/Acquired immune deficiency virus
aComplicated and uncomplicated combined
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conditions) for the condition of diabetes. For all other
conditions, the agreement was weak. This agrees with
previous comparison of the Charlson and RxRisk-V in a
cohort of older non-joint arthroplasty Australian veterans
[38]. Because of this lack of agreement amongst measure-
ments, it is necessary to understand what measurements
are used by different studies. A study using only diagnoses
based measures to identify congestive heart failure, hyper-
tension, or depression will underestimate these diagnoses,
while a study using only RxRisk-V will underestimate renal
disease/failure, dementia, and alcohol abuse. Underestimat-
ing these co-morbidities can impact study estimates. Utiliz-
ing validated measures is also recommended to insure that
comparisons with other study results are possible.
Table 3 Agreement between each co-morbidity measure of individual conditions. Cohen’s Kappa coefficient and 95 % confidence
intervals for agreement estimations













ƙ (95 % CI) ƙ (95 % CI) ƙ (95 % CI) ƙ (95 % CI) ƙ (95 % CI) ƙ (95 % CI)
Cancer
Malignancies - 0.07 (0.04-0.10) - - 0.06 (0.03-0.08) -
Metastatic cancer - 1.00 (1.00-1.00) - 1.00 (1.00-1.00)
Cardiovascular/blood
Anticoagulation agents/coagulopathy 0.01 (0.00-0.01) 0.00 (0.00-0.01)
Arrhythmias 0.35 (0.33-0.38) - - 0.34 (0.32-0.36) - -
Congestive heart failure 0.26 (0.23-0.28) 0.26 (0.23-0.28) 1.00 (1.00-1.00) 0.18 (0.16-0.20) 0.18 (0.16-0.20) 1.0 (1.00-1.00)
Hypertension (complicated and
uncomplicated)
0.13 (0.11-0.14) - - 0.13 (0.11-0.14) - -
Peripheral vascular disease - - 1.00 (1.00-1.00) - - 1.00 (1.00-1.00)
Endocrine
Diabetes (uncomplicated) 0.63 (0.60-0.65) 0.63 (0.60-0.65) 0.94 (0.93-0.96) 0.61 (0.59-0.63) 0.61 (0.59-0.63) 0.95 (0.95-0.96)
Diabetes (complicated) - - 0.97 (0.96-0.98) - - 0.98 (0.97-0.98)
Hypothyroidism 0.12 (0.09-0.15) - - 0.08 (0.06-0.10) - -
Gastrointestinal
Liver disease (mild) - 0.71 (0.56-0.85) - - 0.76 (0.67-0.86)
Liver disease (severe) or failure - 0.01 (0.00-0.02) - - 0.00 (0.00-0.00) -




- - 0.94 (0.92-0.97) - - 0.95 (0.94-0.97)
Neurologic
Dementia - 0.34 (0.27-0.41) - - 0.36 (0.28-4.43) -
Paralysis (or Paraplegia/Hemiplegia) - - 1.00 (1.00-1.00) - - 1.00 (1.00-1.00)
Psychological/behavioral
Alcohol abuse/dependence 0.06 (0.00-0.12) - - 0.10 (0.05-0.16) - -
Depression 0.07 (0.06-0.08) - 0.06 (0.05-0.07) -
Psychotic illness/psychoses 0.05 (0.01-0.09) - 0.04 (0.01-0.07) -
Renal/urologic
Renal disease/failure 0.11 (0.07-0.15) 0.11 (0.08-0.15) 0.94 (0.92-0.96) 0.07 (0.04-0.10) 0.07 (0.05-0.10) 0.95 (0.94-0.97)
Respiratory
Chronic pulmonary disease - - 1.00 (1.00-1.00) - - 1.00 (1.00-1.00)
aRxRisk-V and Elixhauser have ten conditions in common
bRxRisk-V and Charlson have six conditions in common
cElixhauser and Charlson have 12 conditions in common, six where the diagnoses codes are identical (only 11/5 are shown because no cases of HIV/AIDS were
identified in this sample)
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In addition to the differences in prevalence estimates
of co-morbidities, there are further considerations for
choosing the appropriate measure for co-morbidity
ascertainment. Specifically, within the 64 co-morbidities
identified by all measures used in this study, 28 were only
identified by the RxRisk-V, 11 only by the Elixhauser and
two only by the Charlson. Studies requiring the nutri-
tional/obesity related co-morbidities such as obesity,
blood loss anaemia, deficiency anaemia, fluid and electro-
lyte disorders, and weight loss should use the Elixhauser
measure. Studies that require detail on the specific cardio-
vascular disease a patient is actually being treated for (e.g.
anticoagulation disorder, hyperlipidaemia, ischemic heart
disease/angina, and ischemic heart disease/hypertension)
should use the RxRisk-V for obtaining this information.
The Charlson measure should be used if history of
myocardial infarction or cerebrovascular disease are
needed. If a more comprehensive understanding of a
patients’ co-morbidity profile is necessary, we suggest
using all the co-morbidity indices for both the inclusion of
a greater number of conditions and a likely greater sensi-
tivity in identifying certain conditions and provide greater
amount of information to conduct case mix adjustment.
This study has several limitations. Information bias
due to our use of administrative data, which can suffer
from coding errors, missing data, linkage problems,
and lack of detailed clinical information, was possible.
Additionally, because of our sampling frame the preva-
lence of co-morbidities in our study may not be represen-
tative of the greater population undergoing joint
arthroplasty in Australia or in other countries, where the
median age of TKA and THA cohorts is between 65 and
70 years old. Ours is a sample of patients who are
members of the Australian DVA system, an older patient
population due to how their benefits are granted. Due to
their older age we would expect them to have more co-
morbidities than younger arthroplasty cohorts. However,
they are representative of an increasingly greater number
of patients undergoing joint arthroplasty later in life and
therefore offer valuable information in regards to this
specific demographic.
Our study strengths included the utilisation of a captive
membership population with a comprehensive database of
prescription medications dispensed to its members. Due
to the nature of DVA services payments, all the hospital-
isation and prescriptions our cohort of patients obtains
within Australia is captured. A further strength of our
study is that a previous validation study has shown accept-
able results in using the RxRisk-V in the Australian popu-
lation in identifying co-morbidities as compared to self-
reported conditions [25]. Finally, all patients in our study
cohort have unique identifiers, minimizing the likelihood
of data handling bias when linking their hospitalisation,
demographic, and hospitalisation information.
Conclusion
Co-morbidity measures allow us to efficiently evaluate the
disease burden of large cohorts of patients using existing
data, such as administrative encounter and pharmacy dis-
pensing records. Our study, along with others [38, 39]
shows that the prescription based RxRisk-V measure and
diagnostic based Charlson and Elixhauser measures
identify a different prevalence of disease for the same
conditions and have little agreement amongst them (with
the exception of diabetes). Some conditions were better
detected using prescription medication monitoring, while
others were detected using previously inputted diagnostic
codes. The specific co-morbidity measure should be
chosen based on conditions necessary for that particular
study, the acceptable or desirable degree of sensitivity or
specificity in identifying these co-morbidities, and with
the understanding of limitations involved with each of the
specific measures.
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